Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR.
Powell MA, et al. Among authors: sebastianelli a.
Ann Oncol. 2024 Aug;35(8):728-738. doi: 10.1016/j.annonc.2024.05.546. Epub 2024 Jun 10.
Ann Oncol. 2024.
PMID: 38866180
Free article.
Clinical Trial.